| Bioactivity | Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3]. | ||||||||||||
| Invitro | Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3]. | ||||||||||||
| Name | Enavogliflozin | ||||||||||||
| CAS | 1415472-28-4 | ||||||||||||
| Formula | C24H27ClO6 | ||||||||||||
| Molar Mass | 446.92 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Daewoong speeds up developing antidiabetic Enavogliflozin [2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin [3]. Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong's Enavogliflozin & Janssen Biotech's Golimumab Among Others - ResearchAndMarkets.com |
Enavogliflozin
CAS: 1415472-28-4 F: C24H27ClO6 W: 446.92
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotra
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.